Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zydus Cadila's new oral GLP-1 agonist, ZYOG1, has received Phase I clinical trial permission from the Drug Controller General of India (DCGI). Zydus Cadila claimed that ZYOG1 is the latest addition to the group's pipeline of NMEs in clinical development. The NME – ZYH1, which is undergoing Phase III clinical trials, is used for treating dyslipidemia.
Subscribe to our email newsletter
Zydus Cadila said that the first molecule of the new class of anti-diabetic drugs called Glucagon Like Peptide-1 (GLP -1) agonists was approved by FDA in May 2005.
Glucagon Like Peptide-1 agonists are being used to treat people with type 2 diabetes who have not been able to control their blood sugar levels with oral medicines. It is an injection that acts like the natural hormones in the body that lowers blood sugar.
Zydus Cadila stated that ZYOG1 would represent a GLP-1 agent which is not injected but is taken orally. ZYOG1, when administered by oral route demonstrated beneficial effects in preclinical models on glucose reduction, HbA1c reduction and showed an added benefit of weight loss.
Pankaj Patel, chairman and managing director of Zydus Cadila, said: “The discovery of the new oral GLP-1 agonist, ZYOG1, using our own discovery platform technology, is an achievement for us. This new molecule is expected to address unmet medical needs in treating diabetes.”